EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.
| Revenue (TTM) | $74.07M |
| Gross Profit (TTM) | $32.15M |
| EBITDA | $-22.19M |
| Operating Margin | -41.30% |
| Return on Equity | -124.00% |
| Return on Assets | -20.30% |
| Revenue/Share (TTM) | $1.98 |
| Book Value | $0.52 |
| Price-to-Book | 16.10 |
| Price-to-Sales (TTM) | 2.18 |
| EV/Revenue | 2.369 |
| EV/EBITDA | 1165.78 |
| Quarterly Earnings Growth (YoY) | -62.20% |
| Quarterly Revenue Growth (YoY) | 13.90% |
| Shares Outstanding | $37.48M |
| Float | $28.45M |
| % Insiders | 5.95% |
| % Institutions | 38.87% |
Volatility is currently contracting